ASCO GI 2025: Danish Study Highlights Efficacy and Safety of Single-Cycle Neoadjuvant Pembrolizumab for Localized dMMR Colon Cancer
Findings from the RESET-C study suggest that a single cycle of neoadjuvant pembrolizumab offers high efficacy and manageable safety for patients with localized dMMR colon cancer, as presented at the ASCO Gastrointestinal Cancers Symposium.
Brænder du for at skrive?
Vil du gerne dele din forskning eller dine kliniske erfaringer med dine kollegaer inden for netop dit speciale? Har du en ide til en artikel, som du gerne vil udgive hos os? Send redaktionen en mail på redaktion@bpno.dk
Send mail til redaktionen